These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12531084)

  • 41. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases.
    Welliver TP; Reed JL; Welliver RC
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S92-6. PubMed ID: 18820587
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of respiratory syncytial virus infection.
    Kimpen JL
    Curr Opin Infect Dis; 2001 Jun; 14(3):323-8. PubMed ID: 11964851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Respiratory syncytial virus infection in adults.
    Falsey AR
    Semin Respir Crit Care Med; 2007 Apr; 28(2):171-81. PubMed ID: 17458771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In the trenches: a pediatrician's perspective on prevention and treatment strategies for RSV disease.
    Frogel MP
    Manag Care; 2008 Nov; 17(11 Suppl 12):7-12, discussion 18-9. PubMed ID: 19097557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innate immunity in respiratory syncytial virus bronchiolitis.
    Smyth RL
    Exp Lung Res; 2007 Dec; 33(10):543-7. PubMed ID: 18075829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management strategies for respiratory syncytial virus infections in infants.
    Rodriguez WJ
    J Pediatr; 1999 Aug; 135(2 Pt 2):45-50. PubMed ID: 10431139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches.
    Openshaw PJ; Dean GS; Culley FJ
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S58-64; discussion S64-5. PubMed ID: 12671454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
    Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
    J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RSV disease--is there a role for prevention?
    Lenney W
    Respir Med; 2001 Mar; 95(3):170-2. PubMed ID: 11266232
    [No Abstract]   [Full Text] [Related]  

  • 53. Respiratory syncytial virus bronchiolitis: prevention and treatment.
    Faber TE; Kimpen JL; Bont LJ
    Expert Opin Pharmacother; 2008 Oct; 9(14):2451-8. PubMed ID: 18778183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Timing of bronchiolitis hospitalisations and respiratory syncytial virus immunoprophylaxis in non-metropolitan Western Australia.
    Moore HC; Keil AD; Richmond PC; Lehmann D
    Med J Aust; 2009 Nov; 191(10):574. PubMed ID: 19912095
    [No Abstract]   [Full Text] [Related]  

  • 56. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I; Pilenko C; Bost M
    Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
    Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
    Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Palivizumab and RSV prevention.
    Lenney W
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960342
    [No Abstract]   [Full Text] [Related]  

  • 60. Palivizumab and RSV prevention.
    Carnegie C
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960341
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.